HEALTHPOINT Receives Patent for XENADERM™ Ointment Vehicle
Concerns: drug development, and patent
Released on: 26-Nov-2002
Pharmaceutical form and dosage: Ointment
Packaging: 60- gram tubes
- Pharmaceuticals / Therapeutics
- Prescription drugs (Rx)
- Infectious Diseases
Concerns the following market:
- United States of America
(Fort Worth, TX) — Paul Dorman, CEO and Chairman of DFB Pharmaceuticals, Inc. and Healthpoint Ltd., has announced that the United States Patent and Trademark Office has granted Healthpoint a patent for the ointment vehicle that is the basis for Healthpoint’s Xenaderm™, a prescription-only ointment that promotes healing and acts as a protective covering for wounds.
The patent describes the composition and method of manufacture of a pharmaceutically elegant, topical vegetable oil-based ointment containing hydrogenated castor oil and a drug active. The ointment can be used with and will serve as a vehicle for a wide range of drug active ingredients now and in the future, replacing the use of petroleum-based ointments, according to the company.
Lead inventor was David Jones, a Senior Scientific Advisor in the Research and Development department.
“Xenaderm is formulated to promote healing and provide protection from harmful stimuli such as urine or feces,” said Scott Goodridge, Healthpoint’s Marketing Manager for Skin Management Products. “This combination benefits the largest population of wound patients, including those that suffer from pressure ulcers and skin breakdown in the perineal area due to incontinence.”
Healthpoint is a market leader in innovative tissue management, dermatology, and infection prevention. Since its inception in 1992, Healthpoint has established a strong presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices. Healthpoint has headquarters in Fort Worth, Texas. Website is www.healthpoint.com.
DFB, through its affiliate companies, contract partners, and branded marketing organizations, provides technology-driven products, outsourcing services and in-licensing and out-licensing opportunities to the healthcare industry worldwide.
Contact for this news release: Jay Nisbet